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Abstract: Introduction: One of the consequences of periodontitis is 
periodontal intrabony defects (PID). Various biomaterials have been used 
for its treatment, but there is still no biomaterial considered as the gold 
standard. Current research is focused on the use of platelet-rich plasma (PRP) 
for the treatment of PID. Objective: To determine the clinical effect of PRP 
in the treatment of PID through a systematic review with meta-analysis. 
Materials and Methods: A literature search was conducted until February 
2017 in the biomedical databases: Pubmed, Embase, Scielo, Science Direct, 
SIGLE, LILACS, IBECS, and the Cochrane Central Register of Clinical Trials. 
The criteria for the selection of the studies, which were randomized clinical 
trials, were the following: articles or papers published in the last 5 years, 
reporting clinical effects, with a follow-up time equal to or greater than 
6 months, and a sample size equal to or greater than 10 patients reporting 
the use of PRP as a treatment for PID. The methodological quality of the 
studies was analyzed using the Cochrane Handbook of Systematic Reviews 
of Interventions as a reference. Results: The search strategy yielded nine 
articles reporting a reduction in probing depth and gingival recession, and an 
increase in clinical insertion level when using PRP alone or in combination 
with another biomaterial. Conclusion: The reviewed literature suggests that 
the use of PRP in the treatment of PID has a positive clinical effect.
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INTRODUCTION.
Periodontal disease is a multifactorial and complex condition that 
affects the periodontium. It is characterized by the loss of collagen 
membrane with the subsequent destruction of the periodontal tissues.1-3 
If not treated, the condition will lead to a premature loss of teeth.2,4
The main objectives of periodontal treatment are to eliminate the 
inflammatory process, prevent the progression of periodontal disease, 
maintain natural dentition in optimal health and function, and 
regenerate the lost periodontal tissues.1,5,6 The therapeutic modalities 
currently used to restore periodontal tissues, such as conventional open 
flap debridement (COFD), have shown limited potential to achieve the 
desired results. These techniques fail to regenerate the tissues affected 
by the disease. In addition, current regenerative procedures offer limited 
potential for complete periodontal restoration.4,5
One of the consequences of periodontal disease (periodontitis) is 
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the appearance of periodontal intrabony defects (PID) 
(proximal and/or marginal bone loss). Various biomate-
rials, based on endogenous regenerative technology, have 
been used for treatment, in addition to using autogenous 
and allogeneic bone grafts. However, there is not any 
biomaterial considered as the gold standard yet for the 
treatment of PID.3,5,7,8
The key to tissue regeneration is to produce a cascade 
of coordinated curative events that can stimulate 
tissue formation. Such modulators include the use of 
growth factors (GFs), the application of extracellular 
matrix proteins, binding factors and the use of bone 
morphogenetic proteins.2,9,10 The potential role of GFs 
in periodontal regeneration is currently the focus of 
research. In recent years, there has been an increase in the 
scientific evidence that demonstrates their effectiveness 
in periodontal regeneration.2,5,11-14
GFs are present in platelet alpha granules, which upon 
release allow the multiplication and development of vascular 
endothelial cells, smooth muscle cells and fibroblasts. 
In addition, they induce multiple effects on cellular 
remodeling and modulate the inflammatory reaction in the 
healing and tissue regeneration processes.1,2,5,10,14-18
GFs include the platelet-derived growth factor 
(PDGF) and transforming growth factor β (TGF-β). 
These factors are the most studied in terms of 
periodontal regeneration. They are known to facilitate 
bone regeneration after bone grafting by increasing 
neoangiogenesis, cellular chemotaxis, mitosis, 
promoting stem cell proliferation and increasing 
osteoconduction.1,2,10,14,19 Other GFs, such as endothelial 
growth factor, vascular endothelial growth factor 
(VEGF), and type 1 insulin-growth factor, have been 
shown to have the potential to improve and accelerate 
the regeneration of hard and soft tissues.1,5,10-15
There is a growing interest in the use of platelet-rich 
plasma (PRP) for the treatment of PID since it is a con-
centrated source of autologous platelets enriched with 
several GFs.2,5,10,14 However, there is a high heterogenei-
ty among the studies that have evaluated the effect of 
PRP in the treatment of PID.2,14,20-22
The aim of this article was to evaluate the clinical 
effect of PRP in the treatment of periodontal intrabony 
defects.
MATERIALS AND METHODS.
This review was carried out according to a research 
protocol previously developed following the guidelines 
established in the PRISMA standards.23
Search methodology.
A broad search strategy was conducted in the biomedical 
databases Pubmed, Embase, Scielo, Science Direct, SIGLE 
(System of Information on Grey Literature in Europe), 
LILACS, IBECS, and in the Cochrane Central Register 
of Clinical Trials. A manual search was also conducted 
in high impact journals of periodontology such as: 
Periodontology 2000, Journal of Clinical Periodontology 
and Journal of Periodontology up to February 2017; using 
a combination of topic or thematic headings with the 
following keywords: (“plasma rico en plaquetas” OR 
“platelet rich plasma” OR “PRP” OR “plasma rich in 
growth factors”) AND (“defecto intraóseo” OR “defecto 
periodontal” OR “intrabony defect” OR “infrabony 
defect” OR “periodontal defect”).
Selection criteria.
The following inclusion criteria were considered: 
articles reporting the use of PRP in the treatment of PID; 
articles reporting clinical effects (reduction in probing 
depth, increase in clinical insertion level and reduction 
in gingival recession) when using PRP in the treatment 
of PID; articles published in the last 5 years, because 
the most current research is also the most rigorously 
conducted and contains the most relevant data; articles 
reporting a follow-up time equal to or greater than 6 
months, whose sample sizes are equal to or greater than 
10 patients, because the longer the follow-up period 
and the larger the sample size, the more representative 
the results will be, reducing the margin of error and 
increasing the level of confidence; articles reporting 
clinical trials without language restriction.
The following exclusion criteria were considered: 
articles reporting the use of PRP as a control group; 
articles published in non-indexed journals.
Process of selection and extraction of data.
The titles and abstracts of all the articles were 
reviewed. Full texts of the articles that appeared to meet 
the selection criteria were obtained.
A checklist was made in duplicate to evaluate the 
studies and to extract the information of interest. Two 
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reviewers (LG and EI) independently performed the 
evaluation of the articles regarding title, author, year of 
publication, type of study, number of patients, age of 
patients, follow-up time, country where it was conducted, 
number of areas treated per group, number of patients 
per group, type of PID treated, reduction in probing 
depth, increase in clinical insertion level, reduction in 
gingival recession, number of centrifugations, activators 
used, post-surgical medication and risk of bias. For the 
resolution of any discrepancy between the reviewers, they 
met and discussed with a third reviewer (SR) in order to 
reach an agreement.
Assessment of the methodological quality and risk of 
bias of the studies
For the assessment of the methodological quality 
and risk of bias, each study was analyzed according 
to the Cochrane Handbook of Systematic Reviews of 
Interventions.24
Analysis of results
Data from each study were placed and analyzed with 
RevMan 5.3 (Cochrane Group, UK).
RESULTS.
The initial search yielded a total of 112 titles; Figure 1 
shows the selection flowchart. Table 1 also shows the 
characteristics and variables considered in the nine selected 
articles. Figure 2 shows the analysis of the methodological 
quality and the risk of bias of the studies.
Figure 3 presents the forest plot for the reduction 
in probing depth when using PRP in the treatment of 
periodontal intrabony defects. Figure 4 shows the forest 
plot for the increase in clinical insertion level when using 
PRP in the treatment of periodontal intrabony defects. 
Figure 5 presents the forest plot for the reduction in gingival 
recession when using PRP in the treatment of periodontal 
intrabony defects.”
Figure 1. Article selection flowchart.
Articles identified in electronic 
searches (database) and journals.
n=112
Articles excluded for being repeated.
n=13
Articles excluded after evaluating their titles.
n=63
Articles excluded after evaluating their abstracts.
n=25
Studies conducted on animals (n=9)
Bibliographic Reviews (n=1)
Systematic Reviews (n=7)
Case reports (n=7)
Articles excluded after evaluating the full text.
n=2
Full text was not available (n=1)
Reporting only medians (n=1)
Articles selected for title reading.
n=99
Articles identified for abstract evaluation.
n=36
Articles identified for full text reading
n=11
Articles included in the review 
and meta-analysis.
n=9
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Figure 2. Risk of bias of the articles.
Figure 3. Forest plot of the event “Reduction of probing depth when using PRP
 in the treatment of periodontal intrabony defects”.
  PRP               Control       Mean difference
Study or Subgroup Mean SD  Total Mean SD Total Weight  IV Random, 95% CI Year
1.1.1 only PRP 
Pradeep 2012 3.77 1.07 17 2.97 0.93 17 12.8% 0.80 (0.13, 1.47) 2012
Agarwal 2016 4.86 2.12 10 2.69 1.37 9 5.2% 2.17 (0.58, 3.76) 2016
Subtotal (95% CI)   27   26 18.0% 1.29 (0.00, 2.57)
Heterogeneity: Tau2=0.55; Chi2=2.42, d
f 
=1 (p=0.12); I2=59%
Test for overall effect: Z=1.96 (p=0.05)
1.1.2 PRP combined with another biomaterial
Hassan 2012 4.97 0.72 6 4.38 0.96 6 9.6% 0.59 (-0.37, 1.55) 2012
Döri 2013 4.9 2.03 12 5 2.39 12 4.4% -010 (-187, 167) 2013
Gupta 2014 3.4 1.97 10 1.9 1.87 10 4.8% 1.50 (-018, 3.18) 2014
Agarwal 2014 3.65 0.63 24 3.65 0.52 24 16.8% 0.00 (-0.33, 0.33) 2014
Khosropanah 2015 4.6 1.4 12 4.2 1.22 12 8.8% 0.40 (-065, 1.15) 2015
Gamal 2016 4.3 0.36 10 3.8 0.42 10 16.6% 0.50 (0.16, 0.84) 2016
Shukla 2016 3.7 1 20 4.05 1.1 20 13.0% -0.35 (-1.00, 0.30) 2016
Agarwal 2016 4.88 1.12 9 2.69 1.37 9 7.9% 2.19 (1.03, 3.35) 2016
Subtotal (95% CI)   103   103 82.0% 0.44 (-0.01, 0.89)
Heterogeneity: Tau2=0.22;  Chi2=21.12,  d
f 
=9 (p=0.004); I2=67%
Test for overall effect: Z=1.91 (p=0.06)
Total (95% CI)   130   129 100.0% 0.59 (0.16, 1.01)
Heterogeneity: Tau2=0.26; Chi2=28.34,  d
f 
=9 (p=0.0008); I2=68%
Test for overall effect: Z=2.68 (p=0.007)
Test for subgroup differences: Chi2=1.49, d
f 
=1 (p=0.22); I2=32.7%
Mean difference 
IV Random, 95% CI
Favours 
(Control)
-2 0 2-4 -4
Favours 
(PRP)
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Figure 4. Forest plot of the event “Increase in clinical insertion level when using PRP 
in the treatment of periodontal intrabony defects”
Figure 5. Forest plot of the event “Reduction in gingival recession when using PRP 
in the treatment of periodontal intrabony defects”.
  PRP   Control   Mean difference
Study or Subgroup Mean SD  Total Mean SD Total Weight  IV Random, 95% CI Year
1.2.1 only PRP
Pradeep 2012 2.93 1.08 17 2.83 0.91 17 12.8% 0.10 (-0.57, 0.77) 2012
Agarwal 2016 4.1 1.47 10 1.27 0.89 9 9.7% 2.83 (1.75, 3.91) 2016
Subtotal(95% CI)   27   26 22.5% 1.43 (-1.24, 4.11)
Heterogeneity: Tau2=3.25; Chi2=17.69, d
f 
=1 (p=<0.0001); I2=94%
Test for overall effect: Z=1.05 (p=0.29)
1.2.2  PRP combined with another biomaterial
Hassan 2012 3.81 0.77 6 2.94 1.1 6 9.7% 0.87(-0.20, 1.94) 2012
Döri 2013 4.3 2.19 12 4.3 2.2 12 5.9% 0.00 (-1.76, 1.76) 2013
Gupta 2014 3.05 2.28 10 1.3 1.86 10 5.6% 1.75 (-007, 3.57) 2014
Agarwal 2014 3.15 0.5 24 2.4 0.61 24 15.2% 0.00 (0.43, 1.07) 2014
Khosropanah 2015 3.7 1.71 12 3.5 1.74 12 7.8% 0.20 (-1.18, 1.58) 2015
Gamal 2016 2 0.58 10 1.8 0.5 10 14.3% 0.20 (-0.27, 0.67) 2016
Shukla 2016 5.62 1.48 20 5 1.46 20 11.0% 0.62 (-0.29, 1.53) 2016
Agarwal 2016 4.26 1.85 9 1.27 0.89 9 8.0% 2.99 (1.65, 4.33) 2016
Subtotal (95% CI)   103   103 77.5% 0.80 (0.30, 1.30)
Heterogeneity: Tau2=0.25;  Chi2=18.00, d
f 
=7 (p=0.01); I2=61%
Test for overall effect: Z=3.13 (p=0.002)
Total(95% CI)   130   129 100.0% 0.94 (0.40, 1.47)
Heterogeneity: Tau2=0.46; Chi2=36.06, d
f 
=9 (p=<0.0001); I2=75%
Test for overall effect: Z=3.43(p=0.0006)
Test for subgroup differences: Chi2=0.21, d
f 
=1 (p=0.65); I2=0%
  PRP   Control   Mean difference
Study or Subgroup Mean SD  Total Mean SD Total Weight  IV Random, 95% CI Year
1.3.1 only PRP 
Pradeep 2012 0.1 0.61 17 -0.27 0.58 17 24.4% 0.37 (-0.03, 0.77) 2012
Agarwal 2016 -2.04 1.15 10 -3.31 0.54 9 15.1% 1.27 (0.47, 2.07) 2016
Subtotal(95% CI)   27   26 39.6% 0.75 (-0.12, 1.62)
Heterogeneity: Tau2=0.30; Chi2=3.93, d
f 
=1(p=0.05); I2=75%
Test for overall effect: Z=1.69 (p=0.09)
1.3.2  PRP combined with another biomaterial
Döri 2013 -0.6 1.91 12 -0.7 1.84 12 6.6% 0.10 (-1.40, 1.60) 2013
Agarwal 2014 -0.54 0.59 24 -1.23 0.47 24 26.9% 0.69 (0.39, 0.99) 2014
Khosropanah 2015 -0.4 1.4 12 -0.9 1.06 12 11.8% 0.50 (-0.49, 1.49) 2015
Agarwal 2016 -1.45 1.08 9 -3.31 0.54 9 15.2% 1.86 (1.07, 2.65) 2016
Subtotal (95% CI)   57   57 60.4% 0.88 (0.21, 1.55)
Heterogeneity: Tau2=0.28;  Chi2=8.63,  d
f 
=3 (p=0.03); I2=65%
Test for overall effect: Z=2.56 (p=0.01)
Total(95% CI)   84   83 100.0% 0.82 (0.38, 1.25)
Heterogeneity:  Tau2=0.16; Chi2=13.66, d
f 
=9(p=0.02); I2=63%
Test for overall effect: Z=3.70 (p=0.0002)
Test for subgroup differences: Chi2=0.05, d
f 
=1(p=0.82); I2=0%
Mean difference 
IV Random, 95% CI
Mean difference 
IV Random, 95% CI
Favours 
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DISCUSSION.
Results revealed that the use of PRP in the treatment 
of PID produced an increase in the clinical insertion 
level, a reduction in probing depth and a reduction in 
gingival recession significantly greater than the control 
treatment. Subgroup analysis showed that all these 
clinical effects were the same if only PRP was used or if 
PRP was combined with another biomaterial.
In this study, a random effects model for the meta-
analysis was used. It was found that there was no difference 
if the randomized controlled trial (RCT) had a parallel 
or cross-over design, since the studies showed positive 
clinical effects for the use of PRP in the treatment of PID. 
This is similar to the findings reported by Smail et al.,34 
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who performed a meta-epidemiological study that did not 
provide sufficient evidence for the systematic differences 
in estimates of the effect of interventions between split-
mouth and parallel-arm RCTs for continuous or binary 
data. In contrast, Hou et al.,2 stated that different study 
designs are not equally effective in assessing the clinical 
efficacy of PRP.
In relation to the use of PRP in the reduction of gingival 
recessions, there are conflicting results. Del Fabbro et al.,20 
and Gao et al.,21 suggest that PRP does not produce signif-
icant results in gingival recessions. However, Fu et al.,35 re-
port that the systematic review and meta-analysis performed 
by Del Fabbro et al.,20 contained a significant number of 
inconsistencies and therefore determined that their level of 
evidence was 2. The same observations are applicable for 
Gao et al.21. For this reason, one of the strengths of this 
review is to have taken into account the suggestions of 
Fu et al.,35 for higher reliability results.
However, the present review also has limitations. 
Some RCTs with a high risk of bias were included. In 
addition, there is variability in obtaining PRP due to 
the different protocols currently in existence and to the 
different commercially available systems.
Despite these limitations, more than half of the 
studies showed a low risk of bias. Consequently, the 
results obtained from this systematic review and meta-
analysis are reliable. The conclusions and the results of 
the systematic reviews that have been carried out on 
this topic,2,14,20,21,36 confirm that using PRP produces 
a positive clinical effect in the treatment of PID, such 
reviews covered RCTs published in years prior to those 
included in this study.
However, these results cannot be generalized due to 
two reasons. First, most RCTs compared in all systematic 
reviews had high heterogeneity. Second, all RCTs are 
from European and Asian countries, but each continent 
and country has its own culture and type of food. These 
factors can significantly influence the PRP preparation and 
its clinical effects. It is recommended to carry out well-
designed RCTs dealing with this issue in other countries.
CONCLUSION.
The clinical effect of PRP in the treatment of PID is 
positive used either alone or in combination with another 
biomaterial. This clinical effect was significant in reducing 
probing depth, reducing gingival recession and increasing 
clinical insertion level, regardless of whether the RCT has 
a parallel or cross-over design.
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